Opko Health, Inc. Release: Data Supporting Once-Weekly Dosing Of hGH-CTP In Growth Hormone Deficient Pediatric Population To Be Presented At The 2014 ICE/ENDO Meeting
5/20/2014 8:38:28 AM
OPKO Health, Inc. (NYSE: OPK), announced that it will present new clinical data on its long-acting human growth hormone product (hGH-CTP) at the ICE/Endo 2014, the joint meeting of The Endocrine Society and The International Congress of Endocrinology in Chicago on June 21st-24th.
OPKO Biologics (formerly PROLOR Biotech) scientists will present pharmacokinetic and pharmacodynamic data from the company's advanced phase 2 trial of hGH-CTP in growth hormone deficient pediatric subjects.
Help employers find you! Check out all the jobs and post your resume.
comments powered by